Table 5. MDR analysis for the survival prediction in patients with locoregionally advanced nasopharyngeal carcinoma.
| The best combination | TBA | CVC | P value a |
|---|---|---|---|
| Overall survival | |||
| rs2243828 | 0.57 | 10/10 | 0.30 |
| rs2243828, rs2032582 | 0.56 | 8/10 | 0.42 |
| rs2032582, rs2279744, rs1136410 | 0.44 | 3/10 | NR b |
| rs2032582, rs1136410, rs1801131, rs2010963 | 0.43 | 3/10 | NR b |
| Progression-free survival | |||
| rs2243828 | 0.64 | 10/10 | 0.06 |
| rs2243828, rs1801131 | 0.62 | 6/10 | 0.11 |
| rs2243828, rs1801131, rs2032582 | 0.53 | 6/10 | 0.67 |
| rs2243828, rs2032582, rs2279744, rs351855 | 0.45 | 4/10 | NR b |
The above SNPs were specified as following: MPO rs2243828, ABCB1 rs2032582, MDM2 rs2279744, ADPRT rs1136410, VEGF rs2010963, MTHFR rs1801131, FGFR4 rs351855.
P value for 1000-fold permutation test.a
b
Negative result, P value nearly equals to 1.00.
Abbreviation: MDR, Multifactor dimensionality reduction; TBA, Testing balanced accuracy; CVC, Cross-validation consistency.